¸ÞÀÎÄÁÆÛ·±½º µÑ°³¯
¸ÞÀÎÄÁÆÛ·±½º µÑ°³¯
7:45am - 8:10am25 ºÐ°£
Registration and Coffee
µî·Ï¡¤Ä¿ÇÇ ºê·¹ÀÌÅ©
µî·Ï¡¤Ä¿ÇÇ ºê·¹ÀÌÅ©
8:10am - 8:15am5 ºÐ°£
Chairperson¡¯s Remarks
ÀÇÀå Àλç
ÀÇÀå Àλç
- Yogesh Sanghvi, PhD - President, Rasayan Inc.
8:15am - 8:45am30 ºÐ°£
Morning Spotlight Presentation: Isolation and Drying of Peptides and 0ligonucleotides - Improved Production Capacities During Large Scale Manufacturing
¸ð´× ½ºÆ÷Æ®¶óÀÌÆ® ÇÁ·¹Á¨Å×ÀÌ¼Ç : ÆéƼµå¿Í ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµåÀÇ ºÐ¸®¿Í ¿°»ö - ´ë±Ô¸ð »ý»ê½Ã »ý»ê´É·ÂÀÇ °³¼±
¸ð´× ½ºÆ÷Æ®¶óÀÌÆ® ÇÁ·¹Á¨Å×ÀÌ¼Ç : ÆéƼµå¿Í ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµåÀÇ ºÐ¸®¿Í ¿°»ö - ´ë±Ô¸ð »ý»ê½Ã »ý»ê´É·ÂÀÇ °³¼±
- Keith Cronce - Chief Operating Officer, Fluid Air, A Division of Spraying Systems
Plenary Session
±âÁ¶ °¿¬ ¼¼¼Ç
±âÁ¶ °¿¬ ¼¼¼Ç
8:45am - 9:15am30 ºÐ°£
mRNA Advances Track
mRNAÀÇ Áøº¸ Æ®·¢
mRNAÀÇ Áøº¸ Æ®·¢
Complete Chemical Synthesis of mRNA for Cancer Vaccine
¾Ï ¹é½Å¿ë mRNAÀÇ ¿ÏÀü ÈÇÐ ÇÕ¼º
¾Ï ¹é½Å¿ë mRNAÀÇ ¿ÏÀü ÈÇÐ ÇÕ¼º
- Hiroshi Abe, PhD - Professor, Department of Chemistry, Graduate School, Nagoya University
9:15am - 9:45am30 ºÐ°£
mRNA Advances Track
mRNAÀÇ Áøº¸ Æ®·¢
mRNAÀÇ Áøº¸ Æ®·¢
Developing the Next Generation RSV Vaccine
Â÷¼¼´ë RSV ¹é½ÅÀÇ °³¹ß
Â÷¼¼´ë RSV ¹é½ÅÀÇ °³¹ß
- Dong Shen, MD, PhD - CEO, RNAimmune, Inc.
9:45am - 10:15am30 ºÐ°£
mRNA Advances Track
mRNAÀÇ Áøº¸ Æ®·¢
mRNAÀÇ Áøº¸ Æ®·¢
RNA Therapy for Asthma
õ½Ä¿ë RNA Ä¡·áÁ¦
õ½Ä¿ë RNA Ä¡·áÁ¦
- Thomas Langenickel, MD, PhD - Chief Medical Officer, Ethris GmbH
10:15am - 10:55am40 ºÐ°£
Networking Refreshment Break with Poster and Exhibit Viewing
³×Æ®¿öÅ· È޽Ľð£, Æ÷½ºÅÍ¡¤Àü½Ã ¿¶÷
³×Æ®¿öÅ· È޽Ľð£, Æ÷½ºÅÍ¡¤Àü½Ã ¿¶÷
Networking Refreshment Break with Poster and Exhibit Viewing
³×Æ®¿öÅ· È޽Ľð£, Æ÷½ºÅÍ¡¤Àü½Ã ¿¶÷
³×Æ®¿öÅ· È޽Ľð£, Æ÷½ºÅÍ¡¤Àü½Ã ¿¶÷
10:20am - 10:35am15 ºÐ°£
TIDES Talks in the Exhibit Hall
TIDES °¿¬È¸(Àü½ÃȦ)
TIDES °¿¬È¸(Àü½ÃȦ)
Initiating CMO Operations at Axolabs Berlin: From Discovery to Commercial Therapeutic Oligonucleotides
Axolabs Berlin¿¡¼ CMO ¾÷¹«ÀÇ ÇØ¼³ : ´ºÅ¬·¹¿ÀƼµå Ä¡·áÁ¦ÀÇ DiscoveryºÎÅÍ Ãâ½Ã±îÁö
Axolabs Berlin¿¡¼ CMO ¾÷¹«ÀÇ ÇØ¼³ : ´ºÅ¬·¹¿ÀƼµå Ä¡·áÁ¦ÀÇ DiscoveryºÎÅÍ Ãâ½Ã±îÁö
- Thomas Rupp - Managing Director, Axolabs Berlin GmbH
Concurrent Conference Tracks
µ¿½Ã ÁøÇà ÄÁÆÛ·±½º Æ®·¢
µ¿½Ã ÁøÇà ÄÁÆÛ·±½º Æ®·¢
10:55am - 11:00am5 ºÐ°£
Oligonucleotide Track
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
Chairperson¡¯s Remarks: Track 1
ÀÇÀå Àλç : Æ®·¢ 1
ÀÇÀå Àλç : Æ®·¢ 1
- Sridhar Vaddeboina, Ph.D. - Vice President, Analytical Development, Wave Life Sciences
10:55am - 11:00am5 ºÐ°£
Peptide Track
ÆéƼµå Æ®·¢
ÆéƼµå Æ®·¢
Chairperson¡¯s Remarks: Track 2
ÀÇÀå Àλç : Æ®·¢ 2
ÀÇÀå Àλç : Æ®·¢ 2
- El Djouhar Rekaï, PhD - Head of Peptide Process Development & Manufacturing, PolyPeptide Group
11:00am - 11:30am30 ºÐ°£
Oligonucleotide Track
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
CMC Strategies for the Characterization of Stereopure Platform Chemistry
ÀÔü ¼ø¼ö Ç÷§Æû Äɹ̽ºÆ®¸®ÀÇ Æ¯¼º Æò°¡¸¦ À§ÇÑ CMC Àü·«
ÀÔü ¼ø¼ö Ç÷§Æû Äɹ̽ºÆ®¸®ÀÇ Æ¯¼º Æò°¡¸¦ À§ÇÑ CMC Àü·«
- Sridhar Vaddeboina, Ph.D. - Vice President, Analytical Development, Wave Life Sciences
11:00am - 11:30am30 ºÐ°£
Peptide Track
ÆéƼµå Æ®·¢
ÆéƼµå Æ®·¢
Industry Perspective on the Selection of Regulatory Starting Materials for Synthetic Peptides
±ÔÁ¦ ´ë»ó ÇÕ¼º ÆéƼµå¿ë Ãâ¹ß ¹°Áú ¼±Åÿ¡ °üÇÑ ¾÷°èÀÇ °ßÇØ
±ÔÁ¦ ´ë»ó ÇÕ¼º ÆéƼµå¿ë Ãâ¹ß ¹°Áú ¼±Åÿ¡ °üÇÑ ¾÷°èÀÇ °ßÇØ
- John Lopez, PhD - Associate Director Science & Technology, Novartis
11:30am - 12:00pm30 ºÐ°£
Oligonucleotide Track
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
Template-independent Enzymatic Synthesis of Natural and Fully Modified siRNA Oligonucleotides
õ¿¬/¿ÏÀü ¼ö½Ä siRNA ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµåÀÇ ºñÁÖÇü ÀÇÁ¸½Ä È¿¼Ò ÇÕ¼º
õ¿¬/¿ÏÀü ¼ö½Ä siRNA ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµåÀÇ ºñÁÖÇü ÀÇÁ¸½Ä È¿¼Ò ÇÕ¼º
- Jonathan Rittichier, PhD - Chief Scientific Officer & Co-Founder, EnPlusOne BioSciences
11:30am - 12:00pm30 ºÐ°£
Peptide Track
ÆéƼµå Æ®·¢
ÆéƼµå Æ®·¢
Impurities in Peptide Drug Substance and Challenges Faced during Registration (in US, EU, Brazil and China Markets) and Commercial Phase
¿ø·áÀǾàǰ Áß ºÒ¼ø¹°°ú µî·Ï(¹Ì±¹¡¤EU¡¤ºê¶óÁú¡¤Áß±¹ ½ÃÀå)¡¤»ó¾÷È ´Ü°è¿¡¼ Á÷¸éÇÏ´Â ¹®Á¦
¿ø·áÀǾàǰ Áß ºÒ¼ø¹°°ú µî·Ï(¹Ì±¹¡¤EU¡¤ºê¶óÁú¡¤Áß±¹ ½ÃÀå)¡¤»ó¾÷È ´Ü°è¿¡¼ Á÷¸éÇÏ´Â ¹®Á¦
- Dinesh Parmar - Associate Director Regulatory Affairs, PolyPeptide Group
12:00pm - 12:30pm30 ºÐ°£
Oligonucleotide Track
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
Empowering Oligonucleotide Therapeutics: From Raw Materials to Manufacturing, and Advanced Delivery Solutions
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Ä¡·áÁ¦ÀÇ °È : ¿øÀç·áºÎÅÍ Á¦Á¶, ±×¸®°í ÷´Ü Àü´Þ ¼Ö·ç¼Ç±îÁö
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Ä¡·áÁ¦ÀÇ °È : ¿øÀç·áºÎÅÍ Á¦Á¶, ±×¸®°í ÷´Ü Àü´Þ ¼Ö·ç¼Ç±îÁö
- Sirat Sikka - Senior Scientist, Applications and Innovation, Thermo Fisher Scientific
12:00pm - 12:30pm30 ºÐ°£
Peptide Track
ÆéƼµå Æ®·¢
ÆéƼµå Æ®·¢
Statistical Design of Experiments in Peptide Process Development
ÆéƼµå ÇÁ·Î¼¼½º °³¹ß¿¡¼ÀÇ Åë°èÀû ½ÇÇè °èȹ¹ý
ÆéƼµå ÇÁ·Î¼¼½º °³¹ß¿¡¼ÀÇ Åë°èÀû ½ÇÇè °èȹ¹ý
- Alaric Desmarchelier, PhD - Business Development Manager - Peptides, Almac Group
12:30pm - 1:40pm70 ºÐ°£
Networking Luncheon with Poster and Exhibit Viewing
³×Æ®¿öÅ· ¿ÀÂùȸ, Æ÷½ºÅÍ¡¤Àü½Ã ¿¶÷
³×Æ®¿öÅ· ¿ÀÂùȸ, Æ÷½ºÅÍ¡¤Àü½Ã ¿¶÷
1:40pm - 1:45pm5 ºÐ°£
Oligonucleotide Track
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
Chairperson¡¯s Remarks: Track 1
ÀÇÀå Àλç : Æ®·¢ 1
ÀÇÀå Àλç : Æ®·¢ 1
- Sridhar Vaddeboina, Ph.D. - Vice President, Analytical Development, Wave Life Sciences
1:40pm - 1:45pm5 ºÐ°£
Peptide Track
ÆéƼµå Æ®·¢
ÆéƼµå Æ®·¢
Chairperson¡¯s Remarks: Track 2
ÀÇÀå Àλç : Æ®·¢ 2
ÀÇÀå Àλç : Æ®·¢ 2
- El Djouhar Rekaï, PhD - Head of Peptide Process Development & Manufacturing, PolyPeptide Group
1:45pm - 2:15pm30 ºÐ°£
Oligonucleotide Track
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
Drug Substance and Drug Product CMC Strategies for Start-Ups and Smaller Companies
½ºÅ¸Æ®¾÷¡¤Áß¼Ò±â¾÷¿ë ¿ø·áÀǾàǰ¡¤Á¦Á¦ CMC Àü·«
½ºÅ¸Æ®¾÷¡¤Áß¼Ò±â¾÷¿ë ¿ø·áÀǾàǰ¡¤Á¦Á¦ CMC Àü·«
- Chris Oswald - Founder, Owner, and Principal Consultant, Coswald Consulting LLC
1:45pm - 2:15pm30 ºÐ°£
Peptide Track
ÆéƼµå Æ®·¢
ÆéƼµå Æ®·¢
Development of an Efficient and Scalable CSPS Process for a Mid-Sized Cyclic Peptide
ÁßÇü °í¸®Çü ÆéƼµå¿ë È¿À²ÀûÀ̸ç È®´ë¡¤Ãà¼Ò °¡´ÉÇÑ CSPS ÇÁ·Î¼¼½ºÀÇ °³¹ß
ÁßÇü °í¸®Çü ÆéƼµå¿ë È¿À²ÀûÀ̸ç È®´ë¡¤Ãà¼Ò °¡´ÉÇÑ CSPS ÇÁ·Î¼¼½ºÀÇ °³¹ß
- Hiroshi Iwamura, PhD - Deputy Head of API Process Development Department, Chugai Pharmaceutical Co., Ltd.
2:15pm - 2:45pm30 ºÐ°£
Oligonucleotide Track
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
NMA Manufacturing Process Development
NMA Á¦Á¶ °øÁ¤ °³¹ß
NMA Á¦Á¶ °øÁ¤ °³¹ß
- Carter Cooperman - Research Associate II, Ionis
2:15pm - 2:45pm30 ºÐ°£
Peptide Track
ÆéƼµå Æ®·¢
ÆéƼµå Æ®·¢
Overcoming Aggregation Challenges in Peptide Manufacturing: Technical Approach and Case Studies
ÆéƼµå Á¦Á¶½Ã ÀÀÁý ¹®Á¦ÀÇ ±Øº¹ : ±â¼úÀû ¾îÇÁ·ÎÄ¡¿Í »ç·Ê ¿¬±¸
ÆéƼµå Á¦Á¶½Ã ÀÀÁý ¹®Á¦ÀÇ ±Øº¹ : ±â¼úÀû ¾îÇÁ·ÎÄ¡¿Í »ç·Ê ¿¬±¸
- El Djouhar Rekaï, PhD - Head of Peptide Process Development & Manufacturing, PolyPeptide Group
2:45pm - 3:15pm30 ºÐ°£
Oligonucleotide Track
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
Advancements in Oligonucleotide Sequencing Capabilities
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ½ÃÄö½Ì ´É·ÂÀÇ Áøº¸
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ½ÃÄö½Ì ´É·ÂÀÇ Áøº¸
- Collin Wetzel - Associate Principal Scientist, Analytical Development, Nitto Avecia
2:45pm - 3:15pm30 ºÐ°£
Peptide Track
ÆéƼµå Æ®·¢
ÆéƼµå Æ®·¢
An Inline Monitoring Method Integrated Flow Chemistry for Peptide Synthesis and Manufacturing
ÆéƼµå ÇÕ¼º¡¤Á¦Á¶¿ë ÀζóÀÎ ¸ð´ÏÅ͸µ ¹æ¹ý°ú ÀÏüÈÇÑ Ç÷οì Äɹ̽ºÆ®¸®
ÆéƼµå ÇÕ¼º¡¤Á¦Á¶¿ë ÀζóÀÎ ¸ð´ÏÅ͸µ ¹æ¹ý°ú ÀÏüÈÇÑ Ç÷οì Äɹ̽ºÆ®¸®
- Pengyu Xu, PhD - President and Representative Director, SynCrest Inc.
3:15pm - 3:45pm30 ºÐ°£
Networking Refreshment Break with Poster and Exhibit Viewing
³×Æ®¿öÅ· È޽Ľð£, Æ÷½ºÅÍ¡¤Àü½Ã ¿¶÷
³×Æ®¿öÅ· È޽Ľð£, Æ÷½ºÅÍ¡¤Àü½Ã ¿¶÷
3:45pm - 4:15pm30 ºÐ°£
Oligonucleotide Track
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
Development of a Kilogram-Scale Manufacturing Route for Guadecitabine: A Dinucleotide DNA Methyltransferase Inhibitor
GuadecitabineÀÇ Å³·Î±×·¥ ±Ô¸ð Á¦Á¶¹ýÀÇ °³¹ß : Dinucleotid DNA Methyltransferase ÀúÇØÁ¦
GuadecitabineÀÇ Å³·Î±×·¥ ±Ô¸ð Á¦Á¶¹ýÀÇ °³¹ß : Dinucleotid DNA Methyltransferase ÀúÇØÁ¦
- Yogesh Sanghvi, PhD - President, Rasayan Inc.
3:45pm - 4:15pm30 ºÐ°£
Peptide Track
ÆéƼµå Æ®·¢
ÆéƼµå Æ®·¢
Improving Robustness and Recovery in a GLP-1 Purification Process
GLP-1 Á¤Á¦ ÇÁ·Î¼¼½º¿¡¼ °ß°í¼º°ú ȸº¹·ÂÀÇ Çâ»ó
GLP-1 Á¤Á¦ ÇÁ·Î¼¼½º¿¡¼ °ß°í¼º°ú ȸº¹·ÂÀÇ Çâ»ó
- Yvan Ruland, PhD - Technology Consultant Chromatography, Sartorius Stedim Singapore
4:15pm - 4:45pm30 ºÐ°£
Oligonucleotide Track
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
Pioneering the Development of Highly Stable Site-Specific Antibody-Oligonucleotide Conjugates (AOC) Using Fc-Targeting Reagents
FcÇ¥Àû ½Ã¾àÀ» ÀÌ¿ëÇÑ °í¾ÈÁ¤Àû¡¤ºÎÀ§ ƯÀ̼º Ç×ü ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå º¹ÇÕü(AOC)ÀÇ
FcÇ¥Àû ½Ã¾àÀ» ÀÌ¿ëÇÑ °í¾ÈÁ¤Àû¡¤ºÎÀ§ ƯÀ̼º Ç×ü ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå º¹ÇÕü(AOC)ÀÇ
- Tsubasa Aoki, PhD - Researcher, Ajinomoto Co.
4:15pm - 4:45pm30 ºÐ°£
Peptide Track
ÆéƼµå Æ®·¢
ÆéƼµå Æ®·¢
Liquid-phase Peptide Fragment Manufacturing Technologies and Workflows
¾×»ó ÆéƼµå ´ÜÆíÀÇ Á¦Á¶ ±â¼ú°ú ¿öÅ©Ç÷οì
¾×»ó ÆéƼµå ´ÜÆíÀÇ Á¦Á¶ ±â¼ú°ú ¿öÅ©Ç÷οì
- Adrian Amador, PhD - Director of Process Chemistry, Cambrex
4:45pm - 5:15pm30 ºÐ°£
Oligonucleotide Track
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Æ®·¢
Oligonucleotide Purification and CMC Strategies - Increasing Efficiencies/Overcoming Challenges
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Á¤Á¦¡¤CMC Àü·« : È¿À² Çâ»ó/¹®Á¦ ±Øº¹
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Á¤Á¦¡¤CMC Àü·« : È¿À² Çâ»ó/¹®Á¦ ±Øº¹
- Robert Gronke, PhD - Senior Principal Scientist, Technical Development, Biogen, Inc
4:45pm - 5:15pm30 ºÐ°£
Peptide Track
ÆéƼµå Æ®·¢
ÆéƼµå Æ®·¢
A Breakthrough for ¡°TIDEs¡± Researchers in CMC: Developing a State-of-the-Art Technology to Improve Upon Traditional Labor-Intensive Methods of Purification
"TIDEs" ¿¬±¸ÀÚ¿¡°Ô CMCÀÇ µ¹ÆÄ±¸ : ±âÁ¸ ³ëµ¿ Áý¾àÀûÀÎ Á¤Á¦¹ýÀ¸·Î ¹Ù²î´Â ÃÖ÷´Ü ±â¼úÀÇ °³¹ß
"TIDEs" ¿¬±¸ÀÚ¿¡°Ô CMCÀÇ µ¹ÆÄ±¸ : ±âÁ¸ ³ëµ¿ Áý¾àÀûÀÎ Á¤Á¦¹ýÀ¸·Î ¹Ù²î´Â ÃÖ÷´Ü ±â¼úÀÇ °³¹ß
- Katsuhiko Miwa - CEO, ChromaJean
5:15pm - 6:15pm60 ºÐ°£
Networking Cocktail Reception with Poster and Exhibit Viewing
³×Æ®¿öÅ· ĬÅ×ÀÏ ¸®¼Á¼Ç, Æ÷½ºÅÍ¡¤Àü½Ã ¿¶÷
³×Æ®¿öÅ· ĬÅ×ÀÏ ¸®¼Á¼Ç, Æ÷½ºÅÍ¡¤Àü½Ã ¿¶÷
6:15pm - 6:20pm5 ºÐ°£
Close of Day Two
µÑ°³¯ Á¾·á
µÑ°³¯ Á¾·á
* ÁÖÃÖÃø »çÁ¤¿¡ µû¶ó »çÀü ¿¹°í¾øÀÌ ÇÁ·Î±×·¥ÀÌ º¯°æµÉ ¼ö ÀÖ½À´Ï´Ù.